Fenofibrate for patients with asymptomatic primary biliary cirrhosis

Table 1 Change in concentrations of laboratory data (mean ± SD)

Laboratory Variable	Before therapy	4 wk	8 wk	12 wk
AST (IU/L)	29.9 ± 8.1	50.0 ± 36.3	46.6 ± 24.9	46.9 ± 28.3
ALT(IU/L)	31.1 ± 13.2	48.6 ± 35.2	57.0 ± 38.9	48.4 ± 42.5
ALP (IU/L)	285.0 ± 114.8	238.5 ± 88.4	200.6 ± 76.7a	186.9 ± 76.2a
γ-GTP(IU/L)	149.6 ± 143.0	147.0 ± 178.6	128.8 ± 128.1	125.2 ± 110.3
LDH (IU/l)	311.2 ± 46.7	318.4 ± 44.8	320.1 ± 59.9	324.6 ± 59.2
TB (mg/dl)	0.7 ± 0.7	0.4 ± 0.2	0.6 ± 0.4	0.6 ± 0.5
IgG (mg/dl)	1 431.4 ± 285.3	-	-	1 415.0 ± 316.1
IgM (mg/dl)	255.8 ± 85.9	-	-	192.9 ± 67.5a

^aP < 0.05 (baseline-matched t-test) vs the serum concentrations prior to the treatment.